MEI Pharma, Inc. (MEIP)

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP) (“MEI” or the “Company”) today announced that it will change its corporate name to Lite Strategy, Inc., reflecting the Company's expansion into a pioneer in digital asset treasury management. Alongside the rebrand, the Company's ticker symbol on the NASDAQ Stock Market will transition from MEIP to LITS, effective at market open on September 11, 2025. The rebranding to Lite Strategy, Inc. underscores the Company's commitment to building.

[UK, July 24, 2025] - BTC As the blockchain industry enters a new round of market cycle, the multi-currency linkage effect gradually emerges, and the price of BTC today starts to rise at 118875.30. According to foreign media reports such as Investing, with the continuous inflow of US spot ETF funds, the acceleration of technology implementation by the Ethereum Layer 2 Industry Alliance, and the launch of the network upgrade of Dogecoin (DOGE), Bitcoin's "safe-haven attribute" as a market value anchor has once again attracted capital favor, and its network computing power and BTC mining income have increased significantly. Another major positive news this week also boosted BTC confidence: MEI Pharmaceuticals (NASDAQ: MEIP) announced that Litecoin (LTC) will be included in the corporate treasury portfolio and completed the allocation of digital assets worth $100 million, which has aroused the capital market's deep attention to the reserve allocation model of encrypted assets. This behavior not only verifies the trust of mainstream institutions in encrypted assets, but also indirectly drives the prices of major currencies including Bitcoin to rise simultaneously. Hashj made timely adjustments to the market and provided new members with a maximum registration reward of $118 for BTC mining experience.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy.

MEI Pharma, Inc. MEIP stock is trading higher on Friday, with a session volume of 35.64 million compared to the average volume of 29.8K, as per data from Benzinga Pro.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company” or “MEI”) today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a price of $3.42 per share, for expected aggregate gross proceeds of approximately $100 million, before deducting placement agent fees and other estimated offering expenses. In connectio.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockh.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its st.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today announced that its Board of Directors has determined unanimously to begin evaluation of the Company's strategic alternatives, including potential transactions as well as an orderly wind down of the Company, if appropriate, in order to maximize the value of its assets for its stockholders. The Company intends to evaluate and engage a financial advisor to assist in this process. In order to best preserve the Company.

Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.

National Bank of Canada FI bought a new stake in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned 0.09% of MEI Pharma at the end of the most recent quarter. MEI Pharma Trading Up 7.5 % MEIP opened at $3.15 on Monday. The stock has a market cap of $20.98 million, a PE ratio of 0.80 and a beta of 0.82. The business’s 50 day moving average is $3.50 and its 200-day moving average is $4.83. MEI Pharma, Inc. has a twelve month low of $2.87 and a twelve month high of $7.97. Analyst Upgrades and Downgrades MEIP has been the subject of a number of analyst reports. StockNews.com began coverage on shares of MEI Pharma in a research report on Wednesday, May 15th. They issued a “buy” rating for the company. Stifel Nicolaus restated a “hold” rating and set a $7.00 price objective on shares of MEI Pharma in a report on Friday, April 12th. Finally, TheStreet lowered shares of MEI Pharma from a “c-” rating to a “d+” rating in a research note on Thursday, February 1st. View Our Latest Stock Analysis on MEIP About MEI Pharma (Free Report) MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. See Also Five stocks we like better than MEI Pharma Stock Sentiment Analysis: How it Works MarketBeat Week in Review – 5/13 – 5/17 How to Calculate Inflation Rate Take-Two Interactive Software Offers 2nd Chance for Investors What to Know About Investing in Penny Stocks Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible violations of state laws. If you own MEI Pharma stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company's Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additiona.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer (“mCRC”) in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation (“OXPHOS”), in combination with bevacizumab (Avastin®) ha.

SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time. Investors and the general public are invited to listen to a live webc.

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of MEI Pharma, Inc. (Nasdaq: MEIP) concerning the Company and its directors' and officers' possible violations of state laws. If you own MEI Pharma stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York, NY 10169 at tkennedy.